Royal Philips Reports Benefits IFR In Assessment Of Coronary Artery Disease

(RTTNews) - Royal Philips (PHG) reported results from two large clinical trials comparing patient outcomes using instant wave-free ratio (iFR) and fractional flow reserve (FFR) in the diagnosis and treatment of heart disease. iFR is a pressure-derived index unique to Philips allowing hyperemia-free physiological assessment of coronary blockages.

The company said the DEFINE FLAIR and iFR Swedeheart trials demonstrate that, compared to FFR, iFR offers reduced procedure time, cost and complexity without degradation of major adverse cardiac events. The two trials showed that iFR offers a faster procedure while almost completely eliminating severe patient symptoms as compared to FFR.